PYPD PolyPid Ltd.

FDA Catalyst Company
5
+0.22  (+5%)
Previous Close 4.78
Open 4.95
52 Week Low 3.92
52 Week High 9.64
Market Cap $97,353,785
Shares 19,470,757
Float 16,491,415
Enterprise Value $69,629,059
Volume 20,990
Av. Daily Volume 33,533
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Raymond James Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/11/2022
JMP Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 09/14/2021
Cantor Fitzgerald Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/30/2021

Latest News

  1. •  Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently

    •  Recruitment Progressing as Planned with Approximately 900 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery

    •  Extended Cash Runway into the Second Quarter of 2023 with $15 million Non-Dilutive Secured Term Loan Facility

    •  Strengthened Executive Management Team

    •  Conference Call Scheduled for Today at 8:30 AM ET

    PETACH TIKVA, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results…

    View Full Article
  2. PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

    Conference Call Dial-In & Webcast Information:

    Date: Wednesday, May 11, 2022
    Time:8:30 AM Eastern Time
    United States:+1 877-870-9135
    Israel:+972 1809 213-985
    International:+44 (0) 2071 928338
    Conference ID:3450787
    Webcast:https://edge.media-server.com/mmc/p/djs2mjt6
    View Full Article
  3. Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients

    PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022. The focus of this year's summit is From Hope to Product The Brilliant Prospect in Nanomedicine and Related Fields.

    Dr. Noam Emanuel, Chief Scientific Officer of PolyPid, will present the abstract, ‘From Bench to Bedside: D-PLEX100 Limits AMR Occurrence in Randomized

    View Full Article
  4. PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection Society (SIS) 2022 Annual Meeting, being held on April 23-26, 2022 in Dallas, TX.

    The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation,' evaluates the addition of D-PLEX100 to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The presentation will include an oral review led by Dr. Anthony Senagore, Senior Medical Director of PolyPid, and will be…

    View Full Article
  5. PETACH TIKVA, Israel, April 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company has entered into a secured loan agreement for up to $15 million with Kreos Capital VI (Expert Fund) LP ("Kreos"). Proceeds from the loan will be used to support global commercialization preparations for the launch of D-PLEX100 for the prevention of abdominal soft tissue surgical site infections (SSIs), as well as further advancement of PolyPid's OncoPLEX development platform and general corporate purposes.

    "This loan facility broadens our financing options and provides us with access, on a non-dilutive basis, to significant additional…

    View Full Article
View All PolyPid Ltd. News